GC4006ANCT07936188
Phase 2 Study of GC4006A in Healthy Adults
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Differences between groups of Neutralizing Antibody Responses
Timeframe: up to 4 weeks
Differences between groups of Binding Antibody Responses
Timeframe: up to 4 weeks
Secondary (7)
Differences between groups of Neutralizing Antibody Responses
Differences between groups of Binding Antibody Responses
Change from baseline of T-Cell Mediated Immune Responses
Incidence of Solicited Local and Systemic Adverse Events
Incidence of Unsolicited Adverse Events
Show 2 moreShow less
Incidence of Immediate Adverse Events
Incidence of Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs)
Arms and interventions
GC4006A (Dose A)Experimental
GC4006A (Dose B)Experimental
ComirnatyActive comparator
Biologicals: GC4006A, COMIRNATY
Sites
1 site in 1 country
- Korea University Guro HospitalSeoul, Seoul, South Korea